ERBB2 and breast cancer: Similarly, poor RFS was also seen among patients with higher FOXP3 expression in HER2−/ER+ breast cancer (P<0.0001, n = 832, Kaplan-Meier Estimates survival analysis, Figure 6), and the median RFS in tumors with high expression and others were 7.83 and 15.93 years, respectively.